TY - JOUR
T1 - Biomimetic nanoarchitecturing
T2 - A disguised attack on cancer cells
AU - Jha, Adrija
AU - Nikam, Ajinkya Nitin
AU - Kulkarni, Sanjay
AU - Mutalik, Sadhana P.
AU - Pandey, Abhijeet
AU - Hegde, Manasa
AU - Rao, Bola Sadashiva Satish
AU - Mutalik, Srinivas
N1 - Funding Information:
The authors are thankful to i) Manipal Academy of Higher Education (MAHE), Manipal, India for providing Postdoctoral Fellowship to Dr. Abhijeet Pandey and for providing Dr. TMA Pai Doctoral Fellowship to Ajinkya N Nikam and Sanjay Kulkarni, ii) Department of Science and Technology (DST), Government of India, New Delhi for providing INSPIRE fellowship to Ms Sadhana P Mutalik and iii) SERB, Government of India, New Delhi for providing Research Fellowship to Ms Manasa Hegde. The authors are also thankful to Manipal College of Pharmaceutical Sciences, MAHE, Manipal, India for providing necessary facilities.
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/1/10
Y1 - 2021/1/10
N2 - With the changing face of healthcare, there is a demand for drug delivery systems that have increased efficacy and biocompatibility. Nanotechnology derived drug carrier systems were found to be ideal candidates to meet these demands. Among the vast number of nanosized delivery systems, biomimetic nanoparticles have been researched at length. These nanoparticles mimic cellular functions and are highly biocompatible. They are also able to avoid clearance by the reticuloendothelial system which increases the time spent by them in the systemic circulation. Additionally, their low immunogenicity and targeting ability increase their significance as drug carriers. Based on their core material we have summarized them as biomimetic inorganic nanoparticles, biomimetic polymeric nanoparticles, and biomimetic lipid nanoparticles. The core then may be coated using membranes derived from erythrocytes, cancer cells, leukocytes, stem cells, and other membranes to endow them with biomimetic properties. They can be used for personalized therapy and diagnosis of a large number of diseases, primarily cancer. This review summarizes the various therapeutic approaches using biomimetic nanoparticles along with their applications in the field of cancer imaging, nucleic acid therapy and theranostic properties. A brief overview about toxicity concerns related to these nanoconstructs has been added to provide knowledge about biocompatibility of such nanoparticles.
AB - With the changing face of healthcare, there is a demand for drug delivery systems that have increased efficacy and biocompatibility. Nanotechnology derived drug carrier systems were found to be ideal candidates to meet these demands. Among the vast number of nanosized delivery systems, biomimetic nanoparticles have been researched at length. These nanoparticles mimic cellular functions and are highly biocompatible. They are also able to avoid clearance by the reticuloendothelial system which increases the time spent by them in the systemic circulation. Additionally, their low immunogenicity and targeting ability increase their significance as drug carriers. Based on their core material we have summarized them as biomimetic inorganic nanoparticles, biomimetic polymeric nanoparticles, and biomimetic lipid nanoparticles. The core then may be coated using membranes derived from erythrocytes, cancer cells, leukocytes, stem cells, and other membranes to endow them with biomimetic properties. They can be used for personalized therapy and diagnosis of a large number of diseases, primarily cancer. This review summarizes the various therapeutic approaches using biomimetic nanoparticles along with their applications in the field of cancer imaging, nucleic acid therapy and theranostic properties. A brief overview about toxicity concerns related to these nanoconstructs has been added to provide knowledge about biocompatibility of such nanoparticles.
UR - http://www.scopus.com/inward/record.url?scp=85097759160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097759160&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2020.12.005
DO - 10.1016/j.jconrel.2020.12.005
M3 - Article
AN - SCOPUS:85097759160
SN - 0168-3659
VL - 329
SP - 413
EP - 433
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -